Targeting the cell cycle in triple negative breast cancer

靶向三阴性乳腺癌的细胞周期

基本信息

  • 批准号:
    8631060
  • 负责人:
  • 金额:
    $ 42.04万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-04-01 至 2016-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The lack of specific targets for triple negative breast cancer (TNBC) patients remains a major challenge as many are likely to fail standard therapy and develop recurrence within the first five years of follow-up. We have identified that an important regulator of the cell cycle, cyclin E, is over expressed in TNBC. This over expression is seen in the form of low molecular weight cleavage products of cyclin E, termed LMW-E, and is present in 70% of all TNBC compared with only 20% of non-triple negative tumors. The LMW-E have increased kinase activity over full-length cyclin E, are oncogenic in a transgenic mouse model and are a novel target for therapy. It is our goal to use LMW-E to identify TNBC patients, which can be targeted for therapy using Roscovitine (seliciclib), a clinically available inhibitor of LMW-E kinase activity. This therapy is most effective when delivered in combination with chemotherapy. TNBC cell lines are more susceptible to synergistic cytotoxicity with Roscovitine and chemotherapy as compared to normal and non-TNBC. Lastly, we show that induction of LMW-E results in genomic instability. As such, a combinatorial approach of Roscovitine with chemotherapy to exploit the genomic instability and impact on DNA damage pathways is warranted in TNBC patients. We hypothesize that LMW-E expression leads to generation of TN breast cancer and that targeting the LMW-E will provide novel targeted and effective therapeutic strategies for TN breast cancer. The following four Specific Aims will test this hypothesis: (1) Apply an integrated genomic-proteomic approach to identify key genes and proteins that drive the aggressive phenotype of LMW-E positive breast cancer as a function of molecular subtypes. (2) Use of in vitro and in vivo xenograft and transgenic mouse model systems to design most effective treatment strategies targeting LMW-E in TNBC. (3) Elucidate the mechanism of synergism between Roscovitine and chemotherapy or PARP inhibition in TNBC. (4) Phase I trial with dose expansion to determine maximum tolerated dose (MTD), response rate (RR) and biologic effects of CDK2 inhibition with roscovitine (Seliciclib) given prior to liposomal doxorubicin in patients with metastatic TNBC. Collectively, the successful completion of this grant will be a step toward providing patients with triple negative breast cancer a personalized approach to therapy, which has the potential of eradicating their disease.
描述(由申请人提供):三阴性乳腺癌(TNBC)患者缺乏特定目标仍然是一个重大挑战,因为许多人可能无法通过标准治疗并在随访的前五年内复发。我们已经确定,细胞周期的重要调节因子,细胞周期蛋白E,在TNBC中过表达。这种过度表达以细胞周期蛋白E的低分子量切割产物的形式出现,称为LMW-E,并且存在于70%的所有TNBC中,而非三阴性肿瘤仅为20%。LMW-E具有比全长细胞周期蛋白E增加的激酶活性,在转基因小鼠模型中是致癌的,并且是治疗的新靶点。我们的目标是使用LMW-E来识别TNBC患者,这些患者可以使用Roscovitine(seliciclib)进行靶向治疗,Roscovitine是一种临床可用的LMW-E激酶活性抑制剂。这种疗法在与化疗联合使用时最有效。与正常和非TNBC相比,TNBC细胞系对Roscovitine和化疗的协同细胞毒性更敏感。最后,我们表明,LMW-E的诱导导致基因组的不稳定性。因此,在TNBC患者中,需要Roscovitine与化疗的组合方法来利用基因组不稳定性和对DNA损伤途径的影响。我们假设LMW-E表达导致TN乳腺癌的产生,靶向LMW-E将为TN乳腺癌提供新的靶向和有效的治疗策略。以下四个具体目标将检验这一假设:(1)应用整合的基因组-蛋白质组学方法来鉴定驱动LMW-E阳性乳腺癌侵袭性表型的关键基因和蛋白质,作为分子亚型的函数。(2)使用体外和体内异种移植物和转基因小鼠模型系统来设计靶向TNBC中LMW-E的最有效治疗策略。(3)阐明Roscovitine与化疗或PARP抑制剂在TNBC中的协同作用机制。(4)在转移性TNBC患者中进行剂量扩展的I期试验,以确定在脂质体多柔比星之前给予roscovitine(Seliciclib)抑制CDK 2的最大耐受剂量(MTD)、缓解率(RR)和生物效应。总的来说,这笔赠款的成功完成将是向三阴性乳腺癌患者提供个性化治疗方法的一步,这有可能根除他们的疾病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KHANDAN KEYOMARSI其他文献

KHANDAN KEYOMARSI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KHANDAN KEYOMARSI', 18)}}的其他基金

Targeting STAT3 for the Treatment of CDK4/6 Inhibitor Resistant Advanced Estrogen Receptor Positive Breast Cancer Patients
靶向 STAT3 治疗 CDK4/6 抑制剂耐药的晚期雌激素受体阳性乳腺癌患者
  • 批准号:
    10316167
  • 财政年份:
    2020
  • 资助金额:
    $ 42.04万
  • 项目类别:
UPWARDS Training Program (Underrepresented Minorities Working Towards Research Diversity in Science)
UPWARDS 培训计划(代表性不足的少数族裔致力于科学研究多样性)
  • 批准号:
    10023785
  • 财政年份:
    2020
  • 资助金额:
    $ 42.04万
  • 项目类别:
UPWARDS Training Program (Underrepresented Minorities Working Towards Research Diversity in Science)
UPWARDS 培训计划(代表性不足的少数族裔致力于科学研究多样性)
  • 批准号:
    10252909
  • 财政年份:
    2020
  • 资助金额:
    $ 42.04万
  • 项目类别:
Targeting STAT3 for the Treatment of CDK4/6 Inhibitor Resistant Advanced Estrogen Receptor Positive Breast Cancer Patients
靶向 STAT3 治疗 CDK4/6 抑制剂耐药的晚期雌激素受体阳性乳腺癌患者
  • 批准号:
    10097489
  • 财政年份:
    2020
  • 资助金额:
    $ 42.04万
  • 项目类别:
Cytoplasmic cyclin E is an early event for progression to invasive breast cancer
细胞质周期蛋白 E 是进展为浸润性乳腺癌的早期事件
  • 批准号:
    10550153
  • 财政年份:
    2018
  • 资助金额:
    $ 42.04万
  • 项目类别:
Cytoplasmic cyclin E is an early event for progression to invasive breast cancer
细胞质周期蛋白 E 是进展为浸润性乳腺癌的早期事件
  • 批准号:
    9436336
  • 财政年份:
    2018
  • 资助金额:
    $ 42.04万
  • 项目类别:
Cytoplasmic cyclin E is an early event for progression to invasive breast cancer
细胞质周期蛋白 E 是进展为浸润性乳腺癌的早期事件
  • 批准号:
    10337331
  • 财政年份:
    2018
  • 资助金额:
    $ 42.04万
  • 项目类别:
Cytoplasmic cyclin E is an early event for progression to invasive breast cancer
细胞质周期蛋白 E 是进展为浸润性乳腺癌的早期事件
  • 批准号:
    10113558
  • 财政年份:
    2018
  • 资助金额:
    $ 42.04万
  • 项目类别:
Targeting the cell cycle in triple negative breast cancer
靶向三阴性乳腺癌的细胞周期
  • 批准号:
    8250334
  • 财政年份:
    2011
  • 资助金额:
    $ 42.04万
  • 项目类别:
Targeting the cell cycle in triple negative breast cancer
靶向三阴性乳腺癌的细胞周期
  • 批准号:
    8454512
  • 财政年份:
    2011
  • 资助金额:
    $ 42.04万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 42.04万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 42.04万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.04万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.04万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 42.04万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.04万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 42.04万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 42.04万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 42.04万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.04万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了